Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0677 in Alzheimer's Disease
NCT00074529Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2003
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MK-0677 25 mg with Placebo (2 arms). Primary endpoints: Cognitive function at 12 months and Safety and tolerability at 12 months. Started Oct 2003; status: completed.
02
Drugs
ibutamoren
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00074529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074529.